FDA AVANDIA Hearing – Day Two

Wednesday, July 14th, 2010

Today officials meet again in Gaithersburg, Maryland to discuss the fate of the diabetes drug Avandia. FDA decision-makers are given instructions to answer multiple-choice questions that start with the following: Please select the following: A. Avandia (Rosiglitazone) should continue on the market and the black box warning should be removed. B. Avandia should be taken off the market or C. I cannot make a decision with the provided information.

We have reviewed many documents and studies that show Avandia does increase the risk of Ischemic Cardiovascular Events (ICE). We choose option B and believe people who suffered from harmful side effects while taking Avandia should be allowed to receive justice for Glaxo Smith Klein’s negligence.

If you have or are taking Avandia (Rosiglitazone) please seek out the assistance of the Branch Law Firm. We have the resources to take action against the large corporation, Glaxo Smith Klein (GSK), for the wrongdoings and substantial safety concerns that have occurred.